Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP285578.RAQzuPjVIFn4r30bnHKfbTeV4eY86m1Sto9K2YiyO0rH0130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP285578.RAQzuPjVIFn4r30bnHKfbTeV4eY86m1Sto9K2YiyO0rH0130_provenance.
• NP884248.RATdhyOuYpsOWSyYedXddzqR_7iDD8Lnbw8HTvSHYdjgs130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP884248.RATdhyOuYpsOWSyYedXddzqR_7iDD8Lnbw8HTvSHYdjgs130_provenance.
• NP777931.RAYt5OcdbtvXOcjp41YvwH53dDD8Ms4-IY1PQ35ULQpNU130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP777931.RAYt5OcdbtvXOcjp41YvwH53dDD8Ms4-IY1PQ35ULQpNU130_provenance.
• NP229835.RAev0tR_oXRjF_CtxSXVDZzPl91LQJjetl777iRljOLss130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP229835.RAev0tR_oXRjF_CtxSXVDZzPl91LQJjetl777iRljOLss130_provenance.
• NP273679.RAeOC4jaWAhqmxAC0HW_qJ_gl3SA2sQ7yHwR-Ex5g1Fro130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP273679.RAeOC4jaWAhqmxAC0HW_qJ_gl3SA2sQ7yHwR-Ex5g1Fro130_provenance.
• NP401982.RAoEPYW2cvCGyC1d0Gbl468yIIBu3MD5_iaiwlcMStXtg130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP401982.RAoEPYW2cvCGyC1d0Gbl468yIIBu3MD5_iaiwlcMStXtg130_provenance.
• NP548395.RA7iDPkwr_oMzCnhhl7JpKmpa8Xag1uLko9QvoJXAfscM130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP548395.RA7iDPkwr_oMzCnhhl7JpKmpa8Xag1uLko9QvoJXAfscM130_provenance.
• NP649109.RA5VKkMsDvzk7yh-TqoHLitJhDVtq4YH0-cF-YQVoZAFw130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP649109.RA5VKkMsDvzk7yh-TqoHLitJhDVtq4YH0-cF-YQVoZAFw130_provenance.
• NP468549.RAJtT_1zubmk87GIOzLjUa4mSBvt258MJsqznNVIAxO7I130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468549.RAJtT_1zubmk87GIOzLjUa4mSBvt258MJsqznNVIAxO7I130_provenance.
• NP918580.RAyztS4cpSXwLnoTzZAeqRrKrm-ATn0U1IDpoxg34dTBk130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP918580.RAyztS4cpSXwLnoTzZAeqRrKrm-ATn0U1IDpoxg34dTBk130_provenance.
• NP298381.RA-Yq6K7dEOGD67ZVpQCsKmSpz06I3cwMM9y4rYuJnJ40130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP298381.RA-Yq6K7dEOGD67ZVpQCsKmSpz06I3cwMM9y4rYuJnJ40130_provenance.
• NP263037.RA40ckJhzTiozG7V5XO0-5i0tHN9kK5fk-ZceZjloTCZ0130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP263037.RA40ckJhzTiozG7V5XO0-5i0tHN9kK5fk-ZceZjloTCZ0130_provenance.
• NP962278.RAD86tXrn6esROB4rCgrL6y0GZ4yZOklWVn2Abx4HqFrA130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962278.RAD86tXrn6esROB4rCgrL6y0GZ4yZOklWVn2Abx4HqFrA130_provenance.
• NP622563.RAe_ugv4gbKL3ed1wz8LTxfeX3xMJlYaZNCjkU_9bm4lY130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622563.RAe_ugv4gbKL3ed1wz8LTxfeX3xMJlYaZNCjkU_9bm4lY130_provenance.
• NP622644.RAbZnXaNG6JuczTFdFxW7iLL0IZWImuMGrOGgotjmLtE4130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622644.RAbZnXaNG6JuczTFdFxW7iLL0IZWImuMGrOGgotjmLtE4130_provenance.
• NP623877.RAVhxBqKZrCe9-aZI_XHKTrW1jQcW2y40-VA7-I0gUY8E130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623877.RAVhxBqKZrCe9-aZI_XHKTrW1jQcW2y40-VA7-I0gUY8E130_provenance.
• NP624575.RAaOYDxqXghQBDEgW8q4K73O1XYf-MH33JqQNOrw8C11g130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624575.RAaOYDxqXghQBDEgW8q4K73O1XYf-MH33JqQNOrw8C11g130_provenance.
• NP625016.RA8PcA5uwMNfTGAVAKUwDnLqb389KCmoizgegAf8frzd0130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625016.RA8PcA5uwMNfTGAVAKUwDnLqb389KCmoizgegAf8frzd0130_provenance.
• NP625719.RA0OoHIHyUPuCNljvqL9fxxHYwux3Cl0A4jDXwqnLOy2c130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625719.RA0OoHIHyUPuCNljvqL9fxxHYwux3Cl0A4jDXwqnLOy2c130_provenance.
• NP621260.RA_IVroVIu4DXj7XAARn5xHW7uzzzVRa0EnklJMKvmUGk130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621260.RA_IVroVIu4DXj7XAARn5xHW7uzzzVRa0EnklJMKvmUGk130_provenance.
• NP623259.RA0NUt6c23KdALLxP0_iERErmZsBzHIK-61LPWyGyN5Wg130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623259.RA0NUt6c23KdALLxP0_iERErmZsBzHIK-61LPWyGyN5Wg130_provenance.
• NP962279.RA4SfJ4-bCmbbKpfm7PWgOXgdwo9IV7Q4do6CnmJUNazw130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962279.RA4SfJ4-bCmbbKpfm7PWgOXgdwo9IV7Q4do6CnmJUNazw130_provenance.
• assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP622138.RAPwuy5DMGe6ypf-lP9KWT3SUp0wUwbDU0o3YWgIWGCak130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622138.RAPwuy5DMGe6ypf-lP9KWT3SUp0wUwbDU0o3YWgIWGCak130_provenance.
• NP625097.RAIEDxMcvK0kd4oQ_6Jdd_NqdcXDz_enpKze0Wf4_a_-Q130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625097.RAIEDxMcvK0kd4oQ_6Jdd_NqdcXDz_enpKze0Wf4_a_-Q130_provenance.
• assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP962280.RATdcbfQ87x9HfI-8vVVg_0v1pzd4N7Fi328p2K0N3oFw130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962280.RATdcbfQ87x9HfI-8vVVg_0v1pzd4N7Fi328p2K0N3oFw130_provenance.
• NP962283.RAQVYJKytPSgkS3uutnvYmXbc6l_rWE1GJ5_PNnQIESLs130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962283.RAQVYJKytPSgkS3uutnvYmXbc6l_rWE1GJ5_PNnQIESLs130_provenance.
• NP962284.RAR4MbsrLuyugHLqaWNA_gFTUXVk-7aC5ZeQpW6nAAWtA130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962284.RAR4MbsrLuyugHLqaWNA_gFTUXVk-7aC5ZeQpW6nAAWtA130_provenance.
• assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP962281.RAJcTTJl5eRm1bjhuB-a22-npsSZ6-PDqhc6PDHhhbOM4130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962281.RAJcTTJl5eRm1bjhuB-a22-npsSZ6-PDqhc6PDHhhbOM4130_provenance.
• NP962282.RAHb9tCAhpo8YIS90G4NNZSQ4PXKSvbQm_7On6aCPYics130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962282.RAHb9tCAhpo8YIS90G4NNZSQ4PXKSvbQm_7On6aCPYics130_provenance.
• NP621169.RAt2-6NBbTPhyVW0Uzek3_IOgQ5sr9dMPhASRafadwNXI130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621169.RAt2-6NBbTPhyVW0Uzek3_IOgQ5sr9dMPhASRafadwNXI130_provenance.
• NP623956.RAmtdNCSGwoMcWCPwV7glS9aHoTwKQIsqwt48n6Pc4LOk130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623956.RAmtdNCSGwoMcWCPwV7glS9aHoTwKQIsqwt48n6Pc4LOk130_provenance.
• NP962285.RAgsP5pDxrz1Qx_ITc-BSDx95Qc32A7JPXIjbilxXfGgA130_assertion description "[ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962285.RAgsP5pDxrz1Qx_ITc-BSDx95Qc32A7JPXIjbilxXfGgA130_provenance.